1. Predominant enhancement of apoptosis induced by methyl jasmonate in bladder cancer cells: therapeutic effect of the Antp-conjugated Smac peptide.
- Author
-
Xiao XY, Jiang GS, Wang L, Lv L, and Zeng FQ
- Subjects
- Antennapedia Homeodomain Protein, Antineoplastic Agents metabolism, Bisbenzimidazole, Caspase 3 metabolism, Caspase 9 metabolism, Drosophila Proteins, Drug Evaluation, Preclinical, Drug Synergism, Fluorescent Dyes, HEK293 Cells, Humans, Molecular Targeted Therapy, Oligopeptides metabolism, Survivin, Tumor Cells, Cultured, Urinary Bladder Neoplasms metabolism, Acetates pharmacology, Antineoplastic Agents pharmacology, Apoptosis drug effects, Cell Survival drug effects, Cyclopentanes pharmacology, Inhibitor of Apoptosis Proteins metabolism, Oligopeptides pharmacology, Oxylipins pharmacology, Urinary Bladder Neoplasms drug therapy, X-Linked Inhibitor of Apoptosis Protein metabolism
- Abstract
Methyl jasmonate (MJ) has recently attracted attention as a promising antitumoral compound because of its highly specific proapoptotic properties in a wide range of malignancies. However, the high doses required to achieve a therapeutic benefit have limited its clinical development. Here, we hypothesize that the family of inhibitor of apoptosis proteins (IAPs) may inhibit MJ-mediated apoptosis in cancer cells. We combined MJ with the IAPs inhibitor, the second mitochondria-derived activator of caspases (Smac) peptide to treat bladder cancer cells. The results showed that the combination of MJ and Smac peptide enhanced the apoptosis-inducing effect in a synergistic manner by releasing and activating IAPs-bounding caspase-3. These findings suggest that the inhibition of IAPs could overcome the resistance of cancer cells to MJ.
- Published
- 2011
- Full Text
- View/download PDF